人脐带间充质干细胞移植治疗失代偿期肝硬化患者安全性的前瞻性对照试验
[Prospective controlled trial of safety of human umbilical cord derived-mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis].
作者信息
Lin Hu, Zhang Zheng, Shi Ming, Xu Ruo-nan, Fu Jun-liang, Geng Hua, Li Yuan-yuan, Yu Shuang-jie, Chen Li-ming, Lv Sa, Wang Fu-sheng
机构信息
The Research Center For Biological Therapy, Beijing 302 Hospital, Beijing, China.
出版信息
Zhonghua Gan Zang Bing Za Zhi. 2012 Jul;20(7):487-91. doi: 10.3760/cma.j.issn.1007-3418.2012.07.002.
OBJECTIVE
To evaluate the safety of human umbilical cord derived-mesenchymal stem cell (UC-MSC) transplantation therapy in patients with decompensated liver cirrhosis.
METHODS
UC-MSCs were transplanted intravenously into patients with decompensated liver cirrhosis. Serum levels of glucose (GLU), total cholesterol (TC), blood urea nitrogen (BUN), alpha fetoprotein (AFP), white blood cells (WBC), and prothrombin activity (PA) were detected at different time points after UC-MSCs transplantation.
RESULTS
Most UC-MSC transplanted patients experienced an improvement in quality of life, to varying degrees. With the exception of low-grade fever in a few patients, side effects and oncogenic events were rare (treatment group: 1/38 vs. control group: 1/16; P more than 0.05). The UC-MSCs transplantation showed no effect on GLU, TC, BUN, AFP, WBC, or PA.
CONCLUSION
UC-MSCs transplantation in patients with decompensated liver cirrhosis is safe and may improve the patient's quality of life.
目的
评估人脐带间充质干细胞（UC-MSC）移植治疗失代偿期肝硬化患者的安全性。
方法
将UC-MSCs静脉注射到失代偿期肝硬化患者体内。在UC-MSCs移植后的不同时间点检测血清葡萄糖（GLU）、总胆固醇（TC）、血尿素氮（BUN）、甲胎蛋白（AFP）、白细胞（WBC）和凝血酶原活性（PA）水平。
结果
大多数接受UC-MSC移植的患者生活质量有不同程度的改善。除少数患者出现低热外，副作用和致癌事件罕见（治疗组：1/38 vs.对照组：1/16；P>0.05）。UC-MSCs移植对GLU、TC、BUN、AFP、WBC或PA无影响。
结论
UC-MSCs移植治疗失代偿期肝硬化患者是安全的，且可能改善患者的生活质量。
Zotero 插件